These presentations will include clinical data, including recent analyses, from the core phase of the Company’s Phase IIb trial with MIN-101 as monotherapy for unmet needs in patients suffering from schizophrenia, particularly negative symptoms.
So they’ll be testing it as monotherapy.
Hope this drug make it to the market soon…!!!
Actually, they HAVE tested it as monotherapy. Sorry.
Positive symptoms were observed to remain stable,
I have no idea what that means.
Actually it probably follows on from this:
To participate in the trial, patients were required to have stable positive and negative symptoms for three months prior to entry.
How long does phase 3 usually take?
Wonder which negative symptoms it would even help. Hoping they discover treatments for anhedonia researching for MDD; that seems plausible.